The library will operate on a duty schedule between 22 December 2025 and 4 January 2026. During this period, it will be possible to upload publications, but all other services will be suspended.
Gligorov, J.,
Ataseven, B.,
Verrill, M.,
De Laurentiis, M.,
Jung, K. H.,
Azim, H. A.,
Al-Sakaff, N.,
Lauer, S.,
Shing, M.,
Pivot, X.,
SafeHer Study Group:
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early greast cancer: safeHer phase III study's primary analysis of 2573 patients.
Eur. J. Cancer. 82, 237-246, 2017.
András, C.,
Tóth, L.,
Molnár, C.,
Tanyi, M.,
Csiki, Z.,
Dezső, B.,
Pósán, J.,
Shemirani, A. H.,
Csiki, E.,
Szántó, J.:
Correlations between Clinicopathological Parameters and Molecular Signatures of Primary Tumors for Patients with Stage T3N0 Colorectal Adenocarcinomas: A Single Center Retrospective Study on 100 Cases.
Hepato-Gastroenterol. 59 (116), 1091-1097, 2012.
Tóth, L.,
András, C.,
Molnár, C.,
Tanyi, M.,
Csiki, Z.,
Molnár, P. P.,
Szántó, J.:
Investigation of β-catenin and E-cadherin expression in Dukes B2 stage colorectal cancer with tissue microarray method: is it a marker of metastatic potential in rectal cancer?.
Pathol. Oncol. Res. 18 (2), 429-437, 2012.
Szántó, J.:
Nem differenciált pajzsmirigy-carcinomák.
In: Az endokrin és anyagcsere-betegségek gyakorlati kézikönyve. Szerk.: Leövey András [et al.], Medicina, Budapest, 217-220, 2011.
Francz, M.,
Egervári, K.,
Kardos, L.,
Tóth, J.,
Nemes, Z.,
Szántó, J.,
Szöllősi, Z.:
Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study.
J. Clin. Pathol. 63 (4), 341-346, 2010.
Tsakiris, I.,
Soós, G.,
Nemes, Z.,
Kiss, S. S.,
András, C.,
Szántó, J.,
Dezső, B.:
The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas: the coexistence predicts a poor prognosis regardless of EGFR levels.
J. Cancer Res. Clin. Oncol. 134 (4), 439-451, 2008.